Swiss pharmaceutical company Roche has initiated a late-stage clinical trial for its Alzheimer's drug trontinemab, aiming to prevent symptoms in high-risk individuals before cognitive decline becomes apparent. The trial seeks to intervene early in the disease process. Recent data presented at the 2025 Alzheimer's Association International Conference (AAIC) showed that 91% of patients receiving a 3.6 mg/kg dose of trontinemab became amyloid negative on brain scans within 28 weeks, based on a PET measurement threshold of 24 centiloids, indicating minimal amyloid plaque presence. Despite one patient death reported during the trial, the drug demonstrated dramatic amyloid reduction and a surprisingly low incidence of amyloid-related imaging abnormalities (ARIA). Additionally, the Alzheimer's treatment landscape is evolving, with companies like NewAmsterdam Pharma testing CETP inhibitors such as obicetrapib for potential disease modification in genetically high-risk patients, and OncoC4 presenting data on immunotherapy as a potential new class of Alzheimer's drugs. Other biopharma firms are also advancing holistic treatment approaches for Alzheimer's disease, reflecting intensified research and development activity in this field.